Overview of CDC Activities

Task Force on Research Specific to Pregnant and Lactating Women

Athena P. Kourtis, MD, PhD, MPH Division of Reproductive Health National Center for Chronic Disease Prevention and Health Promotion Centers for Disease Control and Prevention

August 21, 2017



National Center for Chronic Disease Prevention and Health Promotion

Division of Reproductive Health

Overview

CDC's Mission

Research

- Assessing Risks for Mother/Baby During Pregnancy and Lactation
- Specific Illnesses AND their Treatments
- Global Health
- Surveillance and Data Collection

Clinical Practice Information and Recommendations

- Communications
- Other Collaborative Efforts

CDC Mission

- As the nation's health protection agency, CDC saves lives and protects people from health threats.
- To accomplish our mission, CDC conducts critical science and provides health information that protects our nation and responds when health threats arise.



CDC Research—Assessing Risk Factors During Pregnancy and Lactation

Centers for Birth Defects Research and Prevention

- National Birth Defects Prevention Study
- Birth Defects Study to Evaluate Pregnancy Exposures
- Cohort Studies of Occupational Exposures
- Epidemiological Studies of Medication Use during Pregnancy
- Study to Explore Early Development



Research – National Birth Defects Prevention Study

- The National Birth Defects Prevention Study is one of the largest studies on birth defects ever undertaken in the U.S.
- Researchers collected information about babies born between 1997 and 2011
- Over the course of 14 years of interviews, 43,000 women from 10 states took part in the study
- More than 200 scientific papers have been published from NBDPS data



Research – Birth Defects Study to Evaluate Pregnancy ExposureS

- Next step the Birth Defects Study to Evaluate Pregnancy ExposureS (BD-STEPS) began collecting data on children born on or after January 1, 2014
- Interviewers talk with women (via telephone) about their pregnancy experience and general overall health
- BD-STEPS collect information on 17 birth defects that are common and can incur high costs, including cleft lip and cleft palate, gastroschisis, heart defects, and spina bifida



Research-Regarding Specific Illnesses and Treatments

Research on Immunizations

- Pregnancy Vaccine Effectiveness Network
- Internet Panel Survey of Pregnant Women
- Conducts Surveillance for vaccine preventable and selected respiratory diseases in pregnant and postpartum women and neonates
- Monitors and evaluates the safety and effectiveness of vaccines in pregnant and postpartum women and neonates
- Recommendations for vaccines in pregnant and postpartum women and neonates, including modeling of vaccine impact – using Grading of Recommendations, Assessment, Development, and Evaluation (GRADE) approach – and economic evaluation

Research-Regarding Specific Illnesses and Treatments

Behavioral and Educational Intervention Research

- Brief Screening and education to prevent congenital CMV
- Efficacy of intervention addressing depression in pregnancy and postpartum

Document Impacts of Opioid Use

- Pilot projects on incidence, severity, and outcomes associated with neonatal abstinence syndrome (NAS)
- Tracking trends in prescription opioid use

Research – Immunizations

Pregnancy Vaccine Effectiveness Network

 Established in April 2016 to estimate incidence of influenza and vaccination rates, describe epidemiologic characteristics associated with illness, and estimate influenza vaccine effectiveness

Internet Panel Survey of Pregnant Women

- Conducted in November and April of each year to monitor vaccination trends in pregnant women
- Includes topical questions on current areas of special interest (such as Zika Virus)

Research-Regarding Specific Illnesses and Treatments: Zika

- CDC's Zika Pregnancy and Birth Defects Task Force conducts research and implements programs to reduce the risk and impact of Zika virus infection in pregnant women, infants, and children.
 - Established U.S. Zika Pregnancy and Infant Registries
 - Enhanced surveillance of pregnant women in Colombia, in collaboration with Colombia's Instituto Nacional de Salud
 - Collaborates with Colombia's INS on a cohort study to identify risk factors for Zika virus transmission; the full spectrum of adverse maternal, fetal, and infant health outcomes associated with Zika virus infection; and risk factors for occurrence of these outcomes
 - Conducted more than 300 clinical outreach presentations; released more than 35 scientific publications, 13 clinical guidance updates, and 10 Health Alert Network (HAN) advisories

CDC Research—Improving Outcomes around the World

- Sub-Saharan Africa: Researchers aim to reduce mother-to-child transmission of HIV and improve outcomes for HIV-infected people
- Kenya: Vaccine demonstration project using an Inactivated Influenza Vaccine to vaccinate pregnant women in a high HIV prevalence and malaria-endemic setting
- Thailand: Randomized placebo-controlled trial testing safety and efficacy of a short course antiviral therapy during pregnancy to prevent transmission of HBV to their babies
- China: Randomized controlled trial among HIV-HBV co-infected women to test the safety of tenofovir during pregnancy

CDC Research—Surveillance and Data Collection

- Pregnancy Risk Assessment Monitoring System (PRAMS)
- Maternity Practices in Infant Nutrition and Care (mPINC) Survey
- National Vital Statistics System
- National Health and Nutrition Examination Survey (NHANES)
- National Survey of Family Growth (NSFG)
- National Health Interview Survey (NHIS)

Research on other databases: Truven Marketscan, HealthCare Cost and Utilization Project

Clinical Guidance

- Treating for Two initiative
- U.S. Medical Eligibility Criteria for Contraceptive Use
- Environmental exposure information for providers
 - Prenatal Assessment of Environmental Risks
 - Pediatrics Environmental Health Specialty Units
 - Guidelines for identifying and managing lead exposure in pregnant and lactating women
- Advisory Committee on Immunization Practices
- Ten Steps to Successful Breastfeeding





Safer Medication Use in Pregnancy



Clinical Guidance – CDC's Treating for Two Initiative



Expand and accelerate research to fill knowledge gaps



Evaluate evidence to facilitate reliable guidance



Deliver up-to-date information to support decision making among prescribers, pharmacists, and consumers

Clinical Guidance – Breastfeeding

CDC supports evidence-based strategies in hospitals to help women who choose to breastfeed start and continue breastfeeding

CDC's Three Strategies to Support Breastfeeding

Improve Hospital Support for Breastfeeding

1

Improve Support for Employed Women

2

Improve Community Support for Breastfeeding

3

Our Goal

 Ensure that when a mom wants to breastfeed, she has the supports in place to successfully initiate and meet her goals

Clinical Guidance Materials – CDC Yellow Book



- Includes the latest information about new emerging infectious disease threats including Zika, Ebola and others
 Written for the health
 - professionals who care for international travelers
 - Includes special guidance for pregnant and lactating women who are traveling internationally

 Definitive guide to staying safe and healthy anywhere in the world

Clinical Guidance Materials – U.S. Medical Eligibility Criteria for Contraceptive Use

The U.S. Medical Eligibility **Criteria for Contraceptive Use** are evidence-based clinical guidelines that provide information for healthcare providers on the safety of contraceptive methods for women with certain characteristics or medical conditions, including postpartum and lactating women



Morbidity and Mortality Weekly Report July 29, 2016

U.S. Medical Eligibility Criteria for Contraceptive Use, 2016

Condition	Sab-Condition	Cu-IND	LHGIND	Implant	DHIPA	101	CHC	Condition	Sub-Condition	Cell				Implant	OMPA	202	
		IC		1 0		1 0				1	C	1	<	1 6	1 6	1 6	1
Age		Menarche	Menarche	Menarche	Menarche	Menurcher	Menanche	Dabetes	a) History of gestational divease	1		1		1	10	1	
		53	10	tn .	10	88	80		b) Norwascular disease	-	-	-	-			-	-
		×20 yrs.2	+20 yrs 2	stllyrs1		~18yrsT	=40 yrs 1		i) Non-insulin dependent.		-	2	-	1	2	1	
		3.20 yrs 1	≥20 yrs 1		10-45 yrs 1		≥40 yrs.2		ii) iroufet dependent	-	-		-	-	-	2	1
				5-45 YEL	>45 yrs.2	545 yrs 1			c) Nephropathy/retinopathy/neuropathy/ d) Other vascular disease or diabetes	-	-	-	-	_	-	-	
Anatomical abnormalities	a) Distorted uterine cavity	4	4	A. A. A. 179	1.00	2012/07/21	1	12-12-12-12-12-12-12-12-12-12-12-12-12-1	of >20 years' duration"	1		2		2	3	2	1
	b) Other abnormalities	2	2		1.1.1			Dysmenorthea	Severe	2		1		1	1	1	
Anomias	a) Ebularitemia	2	1000	1	1	1	1000 Carriero	Indometrial cancer*	124,047	4	2	4	2	1	1	1	
	b) Sickle cell disease*	2	100	1	1	1	2	Indometrial hyperplasia		1	1	1	100	1	1	1001	
	c) from deficiency america	2	1	1	1	1	100	Endometriceis	Constant of the second	2		1	10	1	1	1	
Benign ovarian turnors	Uncluding cysts)	1	100		1		101100	Ep-lepsy'	(see otio Drug Interactions)	1		1		P	10	1.	
Breast disease	a) Undiagnosed mass	1	2	2*	2*	2*	2*	Galibladder disease	a) Symptomatic	-							
	h) Ranign hreatt riseasa	1	1	1	1	1	1	CONCERCIÓN (C	@ Tasated by choiseystectomy	1		2		2	2	2	
	c) Family history of cancer	1	1	1	1	1	1		s) Medically treated	1		2		2	2	2	
	d) Breast cancer'								m) Current	1		2		2	2	2	
	0 Current	1	1000	1000	1	4	MONE STOCK		b) Asymptomatic	1		2		2	2	2	
	is Past and no evidence of current.		3	3	3	3	3	Gestational trophoblastic						-		12111	
	disease for 5 years		1.4	2.				disease'	portevacuation) Il Uterine size finst trimester		-		-	1*	1*	1.	-
Breastlending	a) «21 days postpartum			2.	2*	2*	4		E Uterine size tirst tomester								
	b) 21 to 2 sti days postpartum ii With other risk factors for VII		-				-		to Confirmed GIU	2		2*	200	1.	1.	1*	
	 With other risk factors for VII Without other risk factors for VIII 		-	2*	2"	2*	3"		is Undetectable too deepart	-	-	-	-	-	100		-
			-	2"	2"	2"	3.		BbCG levels	12	1.	1.	3*	1	1*	1.	
	c) 30-42 days postpartum i) With other risk factors for VTE	<u> </u>	-		1*	1*	3.		E Decreasing 6 hCG levels	2	1*	2"	1*	1*	12	1.	
	iii Webour other risk factors for Vite		-	1.	1"	10	2"		iii) Persistently elevated B-HCG levels			-	-	1000		1000	
	di x42 daya postpartum		-	1.	1.	12	2	1	or malignant divease with no	2*	1.	2*	1*	1.	1*	1*	
Cerulical cancer	Awaiting towarment	4 7	4 2	2	1	1	1		evidence or suspicion of intrauterine	-12		÷.				1.12	
Cenacal ectinoson	name of construction	-					1		disease in: Persistently elevated 8-hCG levels		-	-	-	_			-
Cervic al intraepritwikal						-	_		or malignant disease, with evidence	41	2*	41	2-	1.	1*	1-	
necolaria		1	2	2	2	1	2		or suspicion of intrasterine disease	1.23	-		- L				
Cytist Ethonis" Deep inscut Hrontikolis (DVT) Palmonary embolism (PC)	a) Mild (compensated)		1.00	1	1	1	1000	Headaches	a) Nonenigraine (mild or severe)	1		1		1	1	100.051	
	b) Severe* (decompresented)	1	3.00	3	3	2	Sec. A star	1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1	b) Migraine					- 100-			
		1*	1.	1.	2*	1*	10.12		il/Without aura (includes menstrual	1				1		1000	
	a) History of DVT/PC, not receiving								migrainei	-	-		-				-
	anticoaculant therapy			-		-	_	History of bariantic	 With aura a: Restrictive procedures 			1		1			
	0 Higher risk for recurrent DV1/PE 81 Lower risk for recurrent DV1/PE	-	2	3	1	1	4	surgery"	California a Cara Managera California			1		1	-		
	 b) Acute DVT/PE 		2	1	1	1	-		b) Malabsorptive procedures	. 1		1		1	1	3	00
	CIDVT/PE and established anticoagulant	4	4	4	-	1		History of cholestasis	a) Pregnancy related			1	-		1	1	10
	therapy for at least 1 months							PROVER OF CHONELINE	b) Past COC related	-	-	2	-	2	2	2	
	0 Higher risk for recurrent DV1/PL	2	2	2	2	2	4.	History of high blood	at the sale region	-		*					
	ii) Lower risk for recurrent DV1/PI	2	2	2	2	2	3+	pressure during		1		1		1	1	1	
	d) Family history dirst-degree relobves)	1	100	1	1	1	1	pregnancy				100			- 10	1.00	
	el Major surgery				-	_		History of Pelvic surgery		1		1		1	1	1	
	I) With piolonged immobilization	Sec. 16.	2	2	2	2	4	NV	a) High risk for HIV	2	2	2	2	1	1.	1	
	i) Without prolonged immobilization	1	1	1	1	1	2		b) HIV infection		1			1.	· P	Deco Un	
	f) Minor surgery without immobilization	1	1	1	1	1	1		0 Chrically well receiving APV therapy	1	1	1	1	If on tr	eatment_se	e Drug inn	ractio
Depressive disorders	10 2510	17	3.	1.	1"	1"	12		iii Not clinically well or not receiving ABV	2	1	2	1	If on tr	eatment, se	e Drug inn	ractio
		1	-	_	-	_			therapy	100	1						_

Communication

CDC's website provides a broad array of consumer information on issues relevant for pregnant and lactating women, including:

- Gestational diabetes
- Zika Infections
- Folic acid
- Preventing birth defects
- Safe medication use in pregnancy
- Pregnancy & opioid pain medication
- **Blood** pressure
- Breastfeeding

PREGNANT OR THINKING ABOUT GETTING PREGNANT?

Prevent to Protect: Prevent Infections for Baby's Protection.

Some infections before and during pregnancy can hurt you and your baby. They can cause serious illness, birth defects, and lifelong disabilities, such as hearing loss or learning problems. Here are some examples of how you can reduce your risk of getting infection during pregnancy to help protect your baby.

Properly prepare food.



Wash your hands before and after preparing food. Do not eat raw or runny eggs or raw sprouts. Avoid unpasteurized (raw) milk and cheese, and other foods made from them.

Talk to your healthcare provider.



- · Talk to your healthcare provider about what you can do to prevent infections such as Zika virus.
- Make sure that you are up-to-date with vaccinations (shots) before getting preomant.
- Talk to your healthcare provider about vaccinations that you should receive during pregnancy.

Protect yourself from animals and insects known to carry diseases such as Zika virus





Agency (EPA) registered insect recellents with one of the following active ingredients: DEET. picaridin, IR3638, or oil of lemon eucalyptus (para-menthane-3.8-diol)

· Stay away from wild or pet rodents, live poultry, lizards and turtles, and do not clean cat litter boxes while prequant.

Maintain good hygiene



- Before preparing or eating foods - After handling raw meat, raw eggs, or
- unwashed vegetables - After being around or touching
- pets, and other animals - After changing diapers or wiping
- runny noses
- · Do not put a young child's food, utensils, drinking cups, or pacifiers in your mouth.

For more information on preventing birth defects, please visit: http://www.cdc.gov/ncbddd/birthdefects/prevention.html



U.S. Department of Health and Human Services Centers for Disease Control and Prevention

Communication Materials



www.cdc.gov/treatingfortwo Safer Medication Use in Pregnancy

your baby stay safe and healthy.

Other Collaborative Efforts

CDC participates in the Federal Interagency Forum on Child and Family Statistics, an interagency group designed to improve both the quality and use of data on children and families by investigating questions of data quality, data measurement, and data integration.

CDC co-chairs the Federal Interagency Breastfeeding Work Group, an interagency group designed to increase sharing of information and expertise, prevent duplication, and increase collaboration on projects and initiatives with mutual goals.

Other Collaborative Efforts

The American Board of Obstetrics and Gynecology and the CDC Foundation established the American Board of Obstetrics and Gynecology/CDC Larry Gilstrap, MD, Fellowship

- Provides training opportunities for obstetricians and gynecologists at the CDC focusing on infectious diseases and sexually transmitted diseases in women and in pregnancy
- Fellowship assigned within CDC's Division of Sexually Transmitted Disease Prevention and collaborates with the Division of Reproductive Health

Thank you

For more information, please contact Centers for Disease Control and Prevention 1600 Clifton Road NE, Atlanta, GA 30333 Telephone: 1-800-CDC-INFO (232-4636)/TTY: 1-888-232-6348 E-mail: cdcinfo@cdc.gov Web: http://www.cdc.gov

The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention.



National Center for Chronic Disease Prevention and Health Promotion

Division of Reproductive Health